{"ticker": {"uuid": "086ee068-bcfb-4acf-8470-0bbde4734933", "symbol": "CLDX", "name": "Celldex Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Celldex Therapeutics CFO Plans to Retire in 2027", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/celldex-therapeutics-cfo-plans-retire-201417068.html", "source_name": "MT Newswires", "published_at": "2026-07-15T20:14:17+00:00", "published_display": "15 Jul 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex CFO Sam Martin to retire in March 2027 By Investing.com", "summary": "Sam Martin, Celldex Therapeutics' Senior Vice President and Chief Financial Officer, announced his retirement effective March 2027. Martin has been with the company's finance team since 2009 and served as CFO since 2017, overseeing a period of strong financial health. Celldex, wh", "url": "https://ca.investing.com/news/stock-market-news/celldex-cfo-sam-martin-to-retire-in-march-2027-93CH-4735977", "source_name": "Investing.com Canada", "published_at": "2026-07-15T20:12:02", "published_display": "15 Jul 2026 20:12", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Starts CFO Search as Martin Plans 2027 Retirement", "summary": "Celldex (NASDAQ:CLDX) announced that its Senior Vice President and Chief Financial Officer, Sam Martin, plans to retire in March 2027. Martin, who has served as CFO since 2017 and has been with Celldex since 2009, will remain in his role during the search for a successor to ensur", "url": "https://www.stocktitan.net/news/CLDX/celldex-announces-planned-transition-of-chief-financial-gshzanxjenkv.html", "source_name": "Stock Titan", "published_at": "2026-07-15T20:12:02", "published_display": "15 Jul 2026 20:12", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Announces Planned Transition of Chief Financial Officer", "summary": "Celldex announced that Sam Martin, Senior Vice President and Chief Financial Officer, plans to retire in 2027. Mr. Martin, who has been with Celldex since 2009 and CFO since 2017, will remain in his role until March 2027 to ensure a smooth transition while the company searches fo", "url": "https://www.globenewswire.com/news-release/2026/07/15/3328085/24180/en/celldex-announces-planned-transition-of-chief-financial-officer.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T20:12:01", "published_display": "15 Jul 2026 20:12", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Therapeutics (NASDAQ: CLDX) CFO to retire around March 2027", "summary": "Celldex Therapeutics announced that its Senior Vice President and Chief Financial Officer, Sam Martin, plans to retire around March 31, 2027. Martin, who has been with the company since 2009 and CFO since 2017, will remain in his role until his successor is appointed to ensure a ", "url": "https://www.stocktitan.net/sec-filings/CLDX/8-k-celldex-therapeutics-inc-reports-material-event-0dc822c61bbf.html", "source_name": "Stock Titan", "published_at": "2026-07-15T20:12:01", "published_display": "15 Jul 2026 20:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Celldex Therapeutics (CLDX) Gets Fresh Index Attention As Valuation Debate Heats Up", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-09T05:38:49+00:00", "published_display": "09 Jul 2026 05:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Celldex Therapeutics, Inc. \u2013 NASDAQ:CLDX", "summary": "The article focuses on the \"Price to sales forward\" financial metric for Celldex Therapeutics, Inc. (NASDAQ: CLDX) as presented on TradingView. It provides a brief financial overview without specific numeric values but mentions the company's stock information and market status. T", "url": "https://www.tradingview.com/symbols/NASDAQ-CLDX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T13:13:07", "published_display": "07 Jul 2026 13:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Celldex Therapeutics, Inc. \u2013 NASDAQ:CLDX", "summary": "This article provides a brief mention of the \"Price to book forward\" for Celldex Therapeutics, Inc. (NASDAQ: CLDX) as listed on TradingView. It appears to be a stub or a data point within a larger financial platform, offering no further analytical content. The primary focus is me", "url": "https://www.tradingview.com/symbols/NASDAQ-CLDX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T02:12:20", "published_display": "07 Jul 2026 02:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Therapeutics (CLDX) Is Up 8.8% After Broad Russell Growth Index Additions Has The Bull Case Changed?", "summary": "Celldex Therapeutics (CLDX) was recently added to several Russell growth indexes, increasing its visibility to institutional investors. While this inclusion and recent share price strength help with liquidity, the core investment risks - clinical trial outcomes for its barzolvoli", "url": "https://www.sahmcapital.com/news/content/celldex-therapeutics-cldx-is-up-88-after-broad-russell-growth-index-additions-has-the-bull-case-changed-2026-07-06", "source_name": "Sahm", "published_at": "2026-07-06T14:41:05", "published_display": "06 Jul 2026 14:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Celldex Therapeutics, Inc. \u2013 NASDAQ:CLDX", "summary": "This page from TradingView provides financial information for Celldex Therapeutics, Inc. (NASDAQ: CLDX), specifically focusing on its forward Price to Earnings (P/E) ratio. The article indicates that the market is closed and no trades have occurred for CLDX, and lists various dat", "url": "https://www.tradingview.com/symbols/NASDAQ-CLDX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T11:10:30", "published_display": "04 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Therapeutics (CLDX) Enters Russell Growth Indexes As Barzolvolimab Data Puts Valuation In Focus", "summary": "Celldex Therapeutics (CLDX) has been added to several Russell growth benchmarks,", "url": "https://www.sahmcapital.com/news/content/celldex-therapeutics-cldx-enters-russell-growth-indexes-as-barzolvolimab-data-puts-valuation-in-focus-2026-07-01", "source_name": "Sahm", "published_at": "2026-07-02T12:42:05", "published_display": "02 Jul 2026 12:42", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CLDX SEC Filings - Celldex Therapeutics Inc 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive resource for Celldex Therapeutics (CLDX) SEC filings, including annual, quarterly, and material event reports, as well as insider trading forms. It details recent filings such as insider stock option grants, beneficial ownership statements, and ", "url": "https://www.stocktitan.net/sec-filings/CLDX/page-5.html", "source_name": "Stock Titan", "published_at": "2026-07-01T12:40:02", "published_display": "01 Jul 2026 12:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex (CLDX) SVP granted 95,000 options at $34.09 strike", "summary": "Celldex Therapeutics, Inc. reported that Margo Heath-Chiozzi, SVP of Regulatory Affairs, was granted 95,000 incentive stock options at an exercise price of $34.09 per share. These options, issued under the company\u2019s 2021 Omnibus Equity Incentive Plan, will vest 25% on June 25, 20", "url": "https://www.stocktitan.net/sec-filings/CLDX/form-4-celldex-therapeutics-inc-insider-trading-activity-5c82b3cffdac.html", "source_name": "Stock Titan", "published_at": "2026-06-30T15:12:04", "published_display": "30 Jun 2026 15:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex (NASDAQ: CLDX) grants SVP & counsel 93,000 stock options", "summary": "Celldex Therapeutics (NASDAQ: CLDX) granted 93,000 incentive stock options to its SVP & General Counsel, Freddy A. Jimenez, with an exercise price of $34.09 per share. These options, issued under the company's 2021 Omnibus Equity Incentive Plan, will vest 25% on June 25, 2027, wi", "url": "https://www.stocktitan.net/sec-filings/CLDX/form-4-celldex-therapeutics-inc-insider-trading-activity-e5c54e4bccb1.html", "source_name": "Stock Titan", "published_at": "2026-06-30T10:39:11", "published_display": "30 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Celldex Therapeutics, Inc. (CLDX) Stock Positioned for Growth Ahead of Potential 2027 Approval?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQZDBKempnLWhPRGo3V0RZejhjTktrWXhYMjRSc1psQXh3d3pHM2lwVFZxT0tzSnRvY0d5ZFEtRGpsWHp5X21vcTFpY213LVF6UjRveFdyeHN5SG9BOXMxTEx5VVpYLTI4NVJ5UHdsSF9PbkRVbEd0NHMzaDNjeTlpNWRybzlaLURrZllhNGNaZE50a0liYXhmZ0pRZGg?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Celldex Therapeutics, Inc. Insider Trading Activity", "summary": "Celldex Therapeutics, Inc. (CLDX) reported insider trading activity where director Denice Torres was granted 26,000 non-qualified stock options. These options allow her to buy common stock at an exercise price of $34.09 per share, granted on June 25, 2026, and expiring on June 25", "url": "https://www.stocktitan.net/sec-filings/CLDX/form-4-celldex-therapeutics-inc-insider-trading-activity-a9355ace0a2d.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:51:52", "published_display": "29 Jun 2026 20:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Therapeutics (CLDX) CFO awarded 93,000 stock options grant", "summary": "Celldex Therapeutics' SVP and CFO, Martin Samuel Bates, was granted 93,000 incentive stock options at an exercise price of $34.09 per share under the company's 2021 Omnibus Equity Incentive Plan. The options begin vesting 25% on June 25, 2027, with the remainder vesting quarterly", "url": "https://www.stocktitan.net/sec-filings/CLDX/form-4-celldex-therapeutics-inc-insider-trading-activity-953186c8e2d0.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:41:52", "published_display": "29 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex (CLDX) SVP awarded 95,000-share stock option grant at $34.09", "summary": "Celldex Therapeutics, Inc.'s SVP of Corporate Affairs & Administration, Sarah Cavanaugh, was granted incentive stock options for 95,000 shares at an exercise price of $34.09 per share. The options will vest 25% on June 25, 2027, with the remainder vesting quarterly over the subse", "url": "https://www.stocktitan.net/sec-filings/CLDX/form-4-celldex-therapeutics-inc-insider-trading-activity-de3090f3c63a.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:41:52", "published_display": "29 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Therapeutics (CLDX) grants 20,000 stock options to senior VP", "summary": "Celldex Therapeutics, Inc. (CLDX) has granted its Senior Vice President and Chief Business Officer, Ronald Pepin, an incentive stock option for 20,000 shares of common stock. The options have an exercise price of $34.09 per share, with 25% vesting on June 25, 2027, and the remain", "url": "https://www.stocktitan.net/sec-filings/CLDX/form-4-celldex-therapeutics-inc-insider-trading-activity-1c4e17d6847d.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:41:52", "published_display": "29 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex (CLDX) CMO Diane Young receives 57,000 stock options grant", "summary": "Celldex Therapeutics, Inc. reported that its SVP and Chief Medical Officer, Diane C. Young, was granted 57,000 Incentive Stock Options. These options, with an exercise price of $34.09 per share, are part of her compensation and will vest over several years, with 25% vesting on Ju", "url": "https://www.stocktitan.net/sec-filings/CLDX/form-4-celldex-therapeutics-inc-insider-trading-activity-b4f9e55766e3.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:41:52", "published_display": "29 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Therapeutics (CLDX) director receives grant of 26,000 stock options", "summary": "Celldex Therapeutics director Herbert J. Conrad was granted 26,000 non-qualified stock options with an exercise price of $34.09 per share, expiring on June 25, 2036. This grant, under the company's 2021 Omnibus Equity Incentive Plan, increases his total option holdings to 26,000 ", "url": "https://www.stocktitan.net/sec-filings/CLDX/form-4-celldex-therapeutics-inc-insider-trading-activity-7ab6e8b61703.html", "source_name": "Stock Titan", "published_at": "2026-06-29T19:41:52", "published_display": "29 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex (CLDX) director receives 26,000 stock options under 2021 incentive plan", "summary": "Celldex Therapeutics, Inc. director Harry Jr Penner was granted 26,000 non-qualified stock options under the company\u2019s 2021 Omnibus Equity Incentive Plan. These options, with an exercise price of $34.09 per share, expire on June 25, 2036, and are compensation-related rather than ", "url": "https://www.stocktitan.net/sec-filings/CLDX/form-4-celldex-therapeutics-inc-insider-trading-activity-4012cd77c708.html", "source_name": "Stock Titan", "published_at": "2026-06-29T19:41:52", "published_display": "29 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Therapeutics, Inc.(NasdaqCM: CLDX) added to Russell 2500 Growth Benchmark", "summary": "Celldex Therapeutics, Inc. (NasdaqCM: CLDX) has been added to the Russell 2500 Growth Benchmark, a significant inclusion that indicates its growing presence in the market. The company is a clinical-stage biotechnology firm focused on developing therapeutics for severe inflammator", "url": "https://www.marketscreener.com/news/celldex-therapeutics-inc-nasdaqcm-cldx-added-to-russell-2500-growth-benchmark-ce7f5fdfda81f720", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T19:41:51", "published_display": "29 Jun 2026 19:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Therapeutics stock hits 52-week high at 35.8 USD", "summary": "Celldex Therapeutics (CLDX) stock reached a 52-week high, closing at $35.80 and trading at $35.92, reflecting a 74.25% increase over the past year. This surge is supported by positive clinical trial data for its CDX-622 antibody and barzolvolimab, which has led to maintained or u", "url": "https://www.investing.com/news/company-news/celldex-therapeutics-stock-hits-52week-high-at-358-usd-93CH-4765606", "source_name": "Investing.com", "published_at": "2026-06-29T09:36:00", "published_display": "29 Jun 2026 09:36", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex (NASDAQ: CLDX) CCO granted 90,000 stock options at $34.09", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOWXJTVm1VZVoyR0pSalZjdl92bGtjRE5hWnpPREF6N1AtTWJCUFVOQkdsTFVQQ2dIeGZDbWFweTVZM09maTZnbEY2OVpKYjRha05femM3NHQwVHQ3UnhxWTJNLTNta19aai1pdzlEd3pFVUNmdU9tSlZnZm9WSFhqVjZyNzJ0cEZma3VnVjNyTEZkMVdGcFFQMHl3S1R0X2tUcWg5NlBYaURYdGxxVWJ2R0FUYWtjbGRUTEE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex (CLDX) director awarded 26,000-share stock option grant as compensation", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPWFg3LW1USlhScmRkSTA0cE9fY3RtQ0J5OXFxNkgzZlZiWkZMMVZXS1VGaUdMSmZsU2VpaXBQem1xRTg2MXVOX1NVYjJJWHlyVjBmOW1mbjJPVC1FVTc0TWFiYzhaaFVnOFlSemNsYzFGb2hrR2M2aFNYUzJqcFFGY3lmNlh1aWYtcFF4OXZQR3VnWWUxLW9yVl9yLThCSkpKVGZMYXZOMkdpdVl6a01oRFRlVl9scThaN1E?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex (CLDX) director receives grant of 26,000 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOQVVpbG40SnBYY0l4bTRRN1pkN2t6Sy1rY2Z5cHM4cDk5eTJvTndWZ3lqSWJQbmQwc2EyZHNYbkFxcXRPclM1SUEwVzBEaVFNOU4wUjBRbWo5dEcxd1NJb3FVSTd5dTFwWkxLNHlPcGczWEZmdGVEcVMxMi1NTEZqM3hpNUxfNEV4cFJrcjdGTllXODZERi1iSDR0WGhFWlljTDc5eG9HdjktZmQtVGc1c1Q0Y3JaYVd4VVE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex (CLDX) director James Marino awarded options on 26,000 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPMS1fU1JUc1NmTHVjV3YzRVQyM2dwYVNDWjFWVUJ6ZTZ3dTJnaVVQSUtDRUNQYko0T0gyTXpFMnM5dU1GY0prdUpBMzlhUTdaTVBrQUdaeEdCTHQ0akVjbC1rSW82RGRzRUxXVm15QWdZT2dSMllsT2pTY1BNN1lRN2NLTk5hcWVNWUhFUkZmSi1VdlE5cWVRYW01ZXQyMWVqNHBQdGoyTFM3bE9ER21CSVppR19tNVFIclE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex (CLDX) CEO Anthony Marucci receives grant of 375,000 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQSHJIaDlrRjJHVTVqZW1HRnQ0cjZwQ3A5QldnbUtMZXAzdmxZNlRtVkRVTkJRbzJBMWN6UTBSMDE2cHltT2hlZkY5d3lxcjJHdFNIQ3dZSlNxazVGbWFXdWNNR2UyZVAyMTFpR0dsNEZ3TWs2UGxiTW9kYjMyc2JEWklHZEw2T0JHSFF0c2Q2NGZnSHVxUW1PcDdfRmZhZ0dPX0JPOEF3TjVwSFJUNGV2Qm9KMEhRWF9JY3c?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex (NASDAQ: CLDX) grants 100,000 options to senior VP & CPDO", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNc1FBV1JaRDN2alJqRnBnWnhucllxSWFBdjkzTGUwQWdjaVpNdmhhTTVILWpWbV9YakREVUxvMWhDR2FfMjZkQTZyY3VISGttbXpzUVFkTTd6a1hoMjlvTVJnWTFhc3F6WmJwZ0VwbmFRN1hadmNOZi1lWHVZQzZvcEdDRTVMNVlTY2RPY0h4enh5Qm5iVlZHTlIyVHNpczMta2RuTUxtSFJ2VGpfN3M5S0J6S1Q4djBDNVE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Therapeutics, Inc.(NasdaqCM: CLDX) added to Russell 3000E Growth Benchmark", "summary": "Celldex Therapeutics, Inc. (NasdaqCM: CLDX) has been added to the Russell 3000E Growth Benchmark, as announced on June 28, 2026. This news follows several other recent updates for the clinical-stage biotechnology company, including presentations of long-term barzolvolimab results", "url": "https://www.marketscreener.com/news/celldex-therapeutics-inc-nasdaqcm-cldx-added-to-russell-3000e-growth-benchmark-ce7f5fdeda89f324", "source_name": "marketscreener.com", "published_at": "2026-06-29T03:40:35", "published_display": "29 Jun 2026 03:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Celldex Therapeutics, Inc. \u2013 NASDAQ:CLDX", "summary": "This article provides an overview of Celldex Therapeutics, Inc. (NASDAQ: CLDX) focusing on its enterprise value to EBIT forward. The content appears to be a financial data page from TradingView, offering financial metrics and other related company information.", "url": "https://www.tradingview.com/symbols/NASDAQ-CLDX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T16:39:13", "published_display": "28 Jun 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Celldex Therapeutics, Inc. \u2013 SWB:TCE2", "summary": "This article displays the \"Price to earnings forward\" metric for Celldex Therapeutics, Inc. (SWB:TCE2) on the TradingView platform. The page shows that the market is closed, with no trades, and provides navigations related to financial data, news, community, forecasts, and other ", "url": "https://www.tradingview.com/symbols/SWB-TCE2/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T03:10:38", "published_display": "28 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Therapeutics, Inc.(NasdaqCM: CLDX) added to Russell 2000 Growth Benchmark", "summary": "Celldex Therapeutics, Inc. (NasdaqCM: CLDX) has been added to the Russell 2000 Growth Benchmark. This news highlights the company's inclusion in a significant small-cap growth index, signaling increased visibility and potential interest from growth-focused investors. The clinical", "url": "https://www.marketscreener.com/news/celldex-therapeutics-inc-nasdaqcm-cldx-added-to-russell-2000-growth-benchmark-ce7f5fdede8ff727", "source_name": "marketscreener.com", "published_at": "2026-06-27T14:09:01", "published_display": "27 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex (CLDX) shareholders back larger equity plan and all directors", "summary": "Celldex Therapeutics, Inc. shareholders at their 2026 annual meeting approved an amendment to the 2021 Omnibus Equity Incentive Plan, increasing shares available for issuance by 3,400,000 to a total of 12,900,000 and clarifying tax withholding terms. All director nominees were el", "url": "https://www.stocktitan.net/sec-filings/CLDX/8-k-celldex-therapeutics-inc-reports-material-event-3de264792fdd.html", "source_name": "Stock Titan", "published_at": "2026-06-26T13:10:40", "published_display": "26 Jun 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/celldex-presents-long-term-barzolvolimab-142100448.html", "source_name": "GlobeNewswire", "published_at": "2026-06-14T14:21:00+00:00", "published_display": "14 Jun 2026 14:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/celldex-presents-positive-first-human-091500876.html", "source_name": "GlobeNewswire", "published_at": "2026-06-14T09:15:00+00:00", "published_display": "14 Jun 2026 09:15", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Therapeutics (CLDX) Stock Valuation Check After Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPX1VNNHg3NFdBQVFVc2IyUThYMGY1X2ZDQlJsWGZKbUpMdWEwc241UWNuVmpwaFp4SDByY2RVTGVHVGNqSEJTaFgxSFphZmsyT1c0NDBWVHhGZlZBWG90SVFKY0tFaUZENlZmTjlFakhGZ3FEbHZkNUlQRUd4VjgyandJdEhKX0pyaHZsTDhUUVdqOTFuLVgwbHNXSWFGOGI5aENrYVZ0bGRqUQ?oc=5", "source_name": "Market source", "published_at": "2026-06-14T07:00:00+00:00", "published_display": "14 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Data At 2026 EAACI Puts Mast Cell Pipeline In Focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxQVU91VFBXMlc5U25UYVN3Tmd6NFdkMGhxQUF2V1VxU2ptRzRpRlF6UTNDRHJXVUFZUnRCSzVfNThpZ09SNFltYkJKUHpzZm05TXEwM21ndGVTS2x0Snc1X2Q5MDJiTkxITlNQeXU2SXE5Z29XOGMtTzR2Tko2dFFTSkQzWUNOMHRBRGtvMVJ5WWgzT1BKTlRRSHptanU5RzJsMDNWU3VuUkYtTVROUEF3RENtTF84bENZMnRFbmphZ0JnQW9BM3JRcUVyU252UFkzMVNiYTFJQ2k4YmVDTm14STdZMG9SekNn0gHuAUFVX3lxTE90XzdFdURYUExNbDlMRzI1ZUdYOXRwdjBfaC1RanBIQUd2QmdiZkM0b2I4dnZ1QjJPVWpEckZtaVBOVW9pZWlXbWExNk5FTlk2M0x4SjNLWW5tSWZnRU50dzcxdm9kalBTOERQNmlKdnNyYzhISFRoQkZqaGdvMXBpMzBzVkgtQzZJbHZwMGQ4NnZBelZHRHpreFEzcmpXWTZ6U09FWlZ6YVg2VUFGN2tJRVJVUnhzSmptMmljNmtzMklIWkZ4THM5RDFaeEpyY2IxZ0NiNUItSlhQRVZHbXcxM3g2YkFHX1FrU1hkVUE?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/celldex-announces-multiple-upcoming-presentations-200100578.html", "source_name": "GlobeNewswire", "published_at": "2026-06-10T20:01:00+00:00", "published_display": "10 Jun 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UBS Adjusts Price Target on Celldex Therapeutics to $45 From $38, Maintains Buy Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/ubs-adjusts-price-target-celldex-135904970.html", "source_name": "MT Newswires", "published_at": "2026-06-10T13:59:04+00:00", "published_display": "10 Jun 2026 13:59", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "State Street (CLDX) reports 2.8M shares, 4.2% stake in CELLDex Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPaWpJaE9iLS1sQUJocW0zZk9nZVlNZFVyNkxESHVjeVBGZG81TTVLd3huRk8tOE9LMS1uYXFoeTlpLVJxUnNuMmhHcXZLN0VuR25RcmlHcWp6QUo2YmdpQS1CUUR4LVdxVU1ZTk5PbzlBcnJLRzdEVU5sbW5pTjVDMlZkSkZTWmJ0VEhrMk9HWnktMHJ0c3VkRHZENnZySUNSeUpvc2NlQ1FlYW1Nelh1cHREUzhlU1Jhei1IMGJXcWdqRkZuT3BYV1pPTQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Celldex: A Mast Cell Reset Story Hiding Inside A CSU Trial (NASDAQ:CLDX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPS2JJWGpFSGhQSnYzenpqZUhPRWlDTVZIZHowWmxNNkdjWEI5b011WnZJTUx2aEFGSmZCWVA3ZTZNMGFiQVhFSlBQakxjM2VrMnJtWFM1VVdlWENGakxLMkpMUEZpUHQzMS11eUY5YlFoTlgxSi1iNTJnUkFPS1UzSVZ6ZXNCVnBibHFRTy1qLUhQYUVvMGRRQ0JGYWdUbVEtZ09FeA?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQcVlGWTVEZjFwMTMydm1mWVVkTGxBOVlTX1RYdWZDaW9zcUE2TEJaaFF3QWhkMk5UU0w3RHAwLUdiRDdRbHBjdnJZYkpnQlhBRWktZDhaTFo4NG9jeHhRcjU4TGl0U2hCWVg3NnltWTlrVW5ZMjlkSF9fMUh2cEJEYWJmeEs4eVU5UEJUOXBLN1ZOaURHeEF2V0RZYTBRZnFfSmVDM2ltRmo?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Celldex sells nearly 11.9M shares, raises $345M in stock deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNVU1lV05SUG1qQl9zQTlodV8yNGV1MUxWWUpBMm5TU3JqOGcwc1B2YkM4X3d5UGZ1QjJMVm9PMWpZS0lVRkhKb3JEeklDOExVNlNBMzRoVmR1cFZ6YXdqcHdYUTBxY09fWklLWmQ2eUNqUzNDaTYwa196QU5GSUVPREF5VUpicFZ4REx1ZzludmZ6RDFzUGtaeTQzYy1SczRaQ1gtTlhXOUlPRVhWVjk0Tk40cW8yTERoZGc3N2tQZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Therapeutics Completes $345 Million Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOWGJFT09Kbm5qallUX3UxaTJnS3ZGRm5oY2NFd01wbkZ4VlRxN2M1ZmhLa2IyUVRkd1BlR2FWelo3S2R6TlZ5aW9ydEFJNVJ0NDA5clRvQW53UTRRM0VtLXVwbWd2dHRXU25CNHpucTRFX0F5d3pxZVUxQ1RhTUp0a0V0Y2JKX3dfVmFHaUI4RHVROTg5MU53dk5ET3pRQ1hxMUJoblZUbUh5UGluYTlV?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex (NASDAQ: CLDX) raises $300M in new common stock sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPYnV4N3ZKdjc1OVl2Vno3ckp5NFBfT1NoeHhUYWNaUEs3bDFpQ1JFSmw3al9FTlRuVV9URFI3RlpmVjE2b0ZIVEQ4V05LZHo2Q29MeUVYN19wY1ZTcnY0WjA5UGJ3MGVlR3QyLUNPZk9Ra1U2Y2MzMG92S1dXUnZzUkFIZlRFa2R1V1hEdEotV0t5MjdCdDY0WGNydERIZzBSbjdRd1VNRGtOcWhvbWk0SHFKbw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Celldex\u2019s US$300 Million Follow-On To Fund Barzolvolimab Altering The Investment Case For CLDX?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOelFjSlZ6b3IxTmNIWVFoa0Y4ZVRHaEQ3d1FKNGc4bndUSS04VU9ZS3pUR1JHNUoyMV91emRkY0Q1dXhnd1ZkNFVxZjNLUHZkV01qUDU0QW9OWFZPZUt1MTd4TGp6czhtdWtkS1RWOHEtNFQ3VldoaGE0M1N2SlFWUlFuVXNOT21RX3VFMXk0eEo4YWVFaEM4?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Announces Proposed Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQRThLNTdFbkk2T2F1ME9EZmRLSkUtNjlmbXRpWk54WmYzbGotNmsxZzhIV2VPWVp1LVBBVHZVWnlMcE9TU2Zvcm9Wcm1rdThiUVpWSllORF85MHZGNFZ5blpaM3dWVXQzWS05SnhLWlhYb3RIb1lzTy12MmdmY0FrbDhwSjdPYzdrQzFnT0k2eUFaZ19wMnByX2ZhSW9SQnlFQ1lqUnNxTHZ0clk5NTI3cFhJUjhVQVBQTEVPU19YVnVTZ1k3TXJBMlJpRjc?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Celldex Therapeutics (CLDX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE00bjlEU1p6YV9qVS1VdGtaOTlYWnhfYm56M08wT3dVdEFNWlRWUS1CQWxsZkZjNTVIUDFXbWRhY2tsS2VzZ2MzdkgyZlBtSmZleUpBamUyTGZLUQ?oc=5", "source_name": "MarketBeat", "published_at": "2015-06-05T09:00:18+00:00", "published_display": "05 Jun 2015 09:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avant Stock Spikes after Merger Agreement with Celldex", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOOFB2Q21oRkRuTGZNb0RKcVI4R0p0d0hTT0VlSDlFSExPTnVFbjhxWHVFN3Q4UXRrWmxiNWhyMlJiWFJIZjduOHNEdkFCT2txV1F6b3V3b2tYUjhFYVJyMlhVU3NTaHZLWnpXcEN5QWRoQm1BUWRrQkY3Vm1qRUxwZUFSY3E3SS1WWHFkNDhyelI?oc=5", "source_name": "Genetic Engineering and Biotechnology News", "published_at": "2007-10-22T07:00:00+00:00", "published_display": "22 Oct 2007 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Celldex Therapeutics CFO Plans to Retire in 2027", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/celldex-therapeutics-cfo-plans-retire-201417068.html", "source_name": "MT Newswires", "published_at": "2026-07-15T20:14:17+00:00", "published_display": "15 Jul 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex CFO Sam Martin to retire in March 2027 By Investing.com", "summary": "Sam Martin, Celldex Therapeutics' Senior Vice President and Chief Financial Officer, announced his retirement effective March 2027. Martin has been with the company's finance team since 2009 and served as CFO since 2017, overseeing a period of strong financial health. Celldex, wh", "url": "https://ca.investing.com/news/stock-market-news/celldex-cfo-sam-martin-to-retire-in-march-2027-93CH-4735977", "source_name": "Investing.com Canada", "published_at": "2026-07-15T20:12:02", "published_display": "15 Jul 2026 20:12", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Starts CFO Search as Martin Plans 2027 Retirement", "summary": "Celldex (NASDAQ:CLDX) announced that its Senior Vice President and Chief Financial Officer, Sam Martin, plans to retire in March 2027. Martin, who has served as CFO since 2017 and has been with Celldex since 2009, will remain in his role during the search for a successor to ensur", "url": "https://www.stocktitan.net/news/CLDX/celldex-announces-planned-transition-of-chief-financial-gshzanxjenkv.html", "source_name": "Stock Titan", "published_at": "2026-07-15T20:12:02", "published_display": "15 Jul 2026 20:12", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Announces Planned Transition of Chief Financial Officer", "summary": "Celldex announced that Sam Martin, Senior Vice President and Chief Financial Officer, plans to retire in 2027. Mr. Martin, who has been with Celldex since 2009 and CFO since 2017, will remain in his role until March 2027 to ensure a smooth transition while the company searches fo", "url": "https://www.globenewswire.com/news-release/2026/07/15/3328085/24180/en/celldex-announces-planned-transition-of-chief-financial-officer.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T20:12:01", "published_display": "15 Jul 2026 20:12", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Therapeutics (NASDAQ: CLDX) CFO to retire around March 2027", "summary": "Celldex Therapeutics announced that its Senior Vice President and Chief Financial Officer, Sam Martin, plans to retire around March 31, 2027. Martin, who has been with the company since 2009 and CFO since 2017, will remain in his role until his successor is appointed to ensure a ", "url": "https://www.stocktitan.net/sec-filings/CLDX/8-k-celldex-therapeutics-inc-reports-material-event-0dc822c61bbf.html", "source_name": "Stock Titan", "published_at": "2026-07-15T20:12:01", "published_display": "15 Jul 2026 20:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Therapeutics (CLDX) Gets Fresh Index Attention As Valuation Debate Heats Up", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-09T05:38:49+00:00", "published_display": "09 Jul 2026 05:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Celldex Therapeutics, Inc. \u2013 NASDAQ:CLDX", "summary": "The article focuses on the \"Price to sales forward\" financial metric for Celldex Therapeutics, Inc. (NASDAQ: CLDX) as presented on TradingView. It provides a brief financial overview without specific numeric values but mentions the company's stock information and market status. T", "url": "https://www.tradingview.com/symbols/NASDAQ-CLDX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T13:13:07", "published_display": "07 Jul 2026 13:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Celldex Therapeutics, Inc. \u2013 NASDAQ:CLDX", "summary": "This article provides a brief mention of the \"Price to book forward\" for Celldex Therapeutics, Inc. (NASDAQ: CLDX) as listed on TradingView. It appears to be a stub or a data point within a larger financial platform, offering no further analytical content. The primary focus is me", "url": "https://www.tradingview.com/symbols/NASDAQ-CLDX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T02:12:20", "published_display": "07 Jul 2026 02:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Therapeutics (CLDX) Is Up 8.8% After Broad Russell Growth Index Additions Has The Bull Case Changed?", "summary": "Celldex Therapeutics (CLDX) was recently added to several Russell growth indexes, increasing its visibility to institutional investors. While this inclusion and recent share price strength help with liquidity, the core investment risks - clinical trial outcomes for its barzolvoli", "url": "https://www.sahmcapital.com/news/content/celldex-therapeutics-cldx-is-up-88-after-broad-russell-growth-index-additions-has-the-bull-case-changed-2026-07-06", "source_name": "Sahm", "published_at": "2026-07-06T14:41:05", "published_display": "06 Jul 2026 14:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Celldex Therapeutics, Inc. \u2013 NASDAQ:CLDX", "summary": "This page from TradingView provides financial information for Celldex Therapeutics, Inc. (NASDAQ: CLDX), specifically focusing on its forward Price to Earnings (P/E) ratio. The article indicates that the market is closed and no trades have occurred for CLDX, and lists various dat", "url": "https://www.tradingview.com/symbols/NASDAQ-CLDX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T11:10:30", "published_display": "04 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Therapeutics (CLDX) Enters Russell Growth Indexes As Barzolvolimab Data Puts Valuation In Focus", "summary": "Celldex Therapeutics (CLDX) has been added to several Russell growth benchmarks,", "url": "https://www.sahmcapital.com/news/content/celldex-therapeutics-cldx-enters-russell-growth-indexes-as-barzolvolimab-data-puts-valuation-in-focus-2026-07-01", "source_name": "Sahm", "published_at": "2026-07-02T12:42:05", "published_display": "02 Jul 2026 12:42", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CLDX SEC Filings - Celldex Therapeutics Inc 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive resource for Celldex Therapeutics (CLDX) SEC filings, including annual, quarterly, and material event reports, as well as insider trading forms. It details recent filings such as insider stock option grants, beneficial ownership statements, and ", "url": "https://www.stocktitan.net/sec-filings/CLDX/page-5.html", "source_name": "Stock Titan", "published_at": "2026-07-01T12:40:02", "published_display": "01 Jul 2026 12:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex (CLDX) SVP granted 95,000 options at $34.09 strike", "summary": "Celldex Therapeutics, Inc. reported that Margo Heath-Chiozzi, SVP of Regulatory Affairs, was granted 95,000 incentive stock options at an exercise price of $34.09 per share. These options, issued under the company\u2019s 2021 Omnibus Equity Incentive Plan, will vest 25% on June 25, 20", "url": "https://www.stocktitan.net/sec-filings/CLDX/form-4-celldex-therapeutics-inc-insider-trading-activity-5c82b3cffdac.html", "source_name": "Stock Titan", "published_at": "2026-06-30T15:12:04", "published_display": "30 Jun 2026 15:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex (NASDAQ: CLDX) grants SVP & counsel 93,000 stock options", "summary": "Celldex Therapeutics (NASDAQ: CLDX) granted 93,000 incentive stock options to its SVP & General Counsel, Freddy A. Jimenez, with an exercise price of $34.09 per share. These options, issued under the company's 2021 Omnibus Equity Incentive Plan, will vest 25% on June 25, 2027, wi", "url": "https://www.stocktitan.net/sec-filings/CLDX/form-4-celldex-therapeutics-inc-insider-trading-activity-e5c54e4bccb1.html", "source_name": "Stock Titan", "published_at": "2026-06-30T10:39:11", "published_display": "30 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Celldex Therapeutics, Inc. (CLDX) Stock Positioned for Growth Ahead of Potential 2027 Approval?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQZDBKempnLWhPRGo3V0RZejhjTktrWXhYMjRSc1psQXh3d3pHM2lwVFZxT0tzSnRvY0d5ZFEtRGpsWHp5X21vcTFpY213LVF6UjRveFdyeHN5SG9BOXMxTEx5VVpYLTI4NVJ5UHdsSF9PbkRVbEd0NHMzaDNjeTlpNWRybzlaLURrZllhNGNaZE50a0liYXhmZ0pRZGg?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Celldex Therapeutics, Inc. Insider Trading Activity", "summary": "Celldex Therapeutics, Inc. (CLDX) reported insider trading activity where director Denice Torres was granted 26,000 non-qualified stock options. These options allow her to buy common stock at an exercise price of $34.09 per share, granted on June 25, 2026, and expiring on June 25", "url": "https://www.stocktitan.net/sec-filings/CLDX/form-4-celldex-therapeutics-inc-insider-trading-activity-a9355ace0a2d.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:51:52", "published_display": "29 Jun 2026 20:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Therapeutics (CLDX) CFO awarded 93,000 stock options grant", "summary": "Celldex Therapeutics' SVP and CFO, Martin Samuel Bates, was granted 93,000 incentive stock options at an exercise price of $34.09 per share under the company's 2021 Omnibus Equity Incentive Plan. The options begin vesting 25% on June 25, 2027, with the remainder vesting quarterly", "url": "https://www.stocktitan.net/sec-filings/CLDX/form-4-celldex-therapeutics-inc-insider-trading-activity-953186c8e2d0.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:41:52", "published_display": "29 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex (CLDX) SVP awarded 95,000-share stock option grant at $34.09", "summary": "Celldex Therapeutics, Inc.'s SVP of Corporate Affairs & Administration, Sarah Cavanaugh, was granted incentive stock options for 95,000 shares at an exercise price of $34.09 per share. The options will vest 25% on June 25, 2027, with the remainder vesting quarterly over the subse", "url": "https://www.stocktitan.net/sec-filings/CLDX/form-4-celldex-therapeutics-inc-insider-trading-activity-de3090f3c63a.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:41:52", "published_display": "29 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Therapeutics (CLDX) grants 20,000 stock options to senior VP", "summary": "Celldex Therapeutics, Inc. (CLDX) has granted its Senior Vice President and Chief Business Officer, Ronald Pepin, an incentive stock option for 20,000 shares of common stock. The options have an exercise price of $34.09 per share, with 25% vesting on June 25, 2027, and the remain", "url": "https://www.stocktitan.net/sec-filings/CLDX/form-4-celldex-therapeutics-inc-insider-trading-activity-1c4e17d6847d.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:41:52", "published_display": "29 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex (CLDX) CMO Diane Young receives 57,000 stock options grant", "summary": "Celldex Therapeutics, Inc. reported that its SVP and Chief Medical Officer, Diane C. Young, was granted 57,000 Incentive Stock Options. These options, with an exercise price of $34.09 per share, are part of her compensation and will vest over several years, with 25% vesting on Ju", "url": "https://www.stocktitan.net/sec-filings/CLDX/form-4-celldex-therapeutics-inc-insider-trading-activity-b4f9e55766e3.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:41:52", "published_display": "29 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Therapeutics (CLDX) director receives grant of 26,000 stock options", "summary": "Celldex Therapeutics director Herbert J. Conrad was granted 26,000 non-qualified stock options with an exercise price of $34.09 per share, expiring on June 25, 2036. This grant, under the company's 2021 Omnibus Equity Incentive Plan, increases his total option holdings to 26,000 ", "url": "https://www.stocktitan.net/sec-filings/CLDX/form-4-celldex-therapeutics-inc-insider-trading-activity-7ab6e8b61703.html", "source_name": "Stock Titan", "published_at": "2026-06-29T19:41:52", "published_display": "29 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex (CLDX) director receives 26,000 stock options under 2021 incentive plan", "summary": "Celldex Therapeutics, Inc. director Harry Jr Penner was granted 26,000 non-qualified stock options under the company\u2019s 2021 Omnibus Equity Incentive Plan. These options, with an exercise price of $34.09 per share, expire on June 25, 2036, and are compensation-related rather than ", "url": "https://www.stocktitan.net/sec-filings/CLDX/form-4-celldex-therapeutics-inc-insider-trading-activity-4012cd77c708.html", "source_name": "Stock Titan", "published_at": "2026-06-29T19:41:52", "published_display": "29 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Therapeutics, Inc.(NasdaqCM: CLDX) added to Russell 2500 Growth Benchmark", "summary": "Celldex Therapeutics, Inc. (NasdaqCM: CLDX) has been added to the Russell 2500 Growth Benchmark, a significant inclusion that indicates its growing presence in the market. The company is a clinical-stage biotechnology firm focused on developing therapeutics for severe inflammator", "url": "https://www.marketscreener.com/news/celldex-therapeutics-inc-nasdaqcm-cldx-added-to-russell-2500-growth-benchmark-ce7f5fdfda81f720", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T19:41:51", "published_display": "29 Jun 2026 19:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Therapeutics stock hits 52-week high at 35.8 USD", "summary": "Celldex Therapeutics (CLDX) stock reached a 52-week high, closing at $35.80 and trading at $35.92, reflecting a 74.25% increase over the past year. This surge is supported by positive clinical trial data for its CDX-622 antibody and barzolvolimab, which has led to maintained or u", "url": "https://www.investing.com/news/company-news/celldex-therapeutics-stock-hits-52week-high-at-358-usd-93CH-4765606", "source_name": "Investing.com", "published_at": "2026-06-29T09:36:00", "published_display": "29 Jun 2026 09:36", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex (NASDAQ: CLDX) CCO granted 90,000 stock options at $34.09", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOWXJTVm1VZVoyR0pSalZjdl92bGtjRE5hWnpPREF6N1AtTWJCUFVOQkdsTFVQQ2dIeGZDbWFweTVZM09maTZnbEY2OVpKYjRha05femM3NHQwVHQ3UnhxWTJNLTNta19aai1pdzlEd3pFVUNmdU9tSlZnZm9WSFhqVjZyNzJ0cEZma3VnVjNyTEZkMVdGcFFQMHl3S1R0X2tUcWg5NlBYaURYdGxxVWJ2R0FUYWtjbGRUTEE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex (CLDX) director awarded 26,000-share stock option grant as compensation", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPWFg3LW1USlhScmRkSTA0cE9fY3RtQ0J5OXFxNkgzZlZiWkZMMVZXS1VGaUdMSmZsU2VpaXBQem1xRTg2MXVOX1NVYjJJWHlyVjBmOW1mbjJPVC1FVTc0TWFiYzhaaFVnOFlSemNsYzFGb2hrR2M2aFNYUzJqcFFGY3lmNlh1aWYtcFF4OXZQR3VnWWUxLW9yVl9yLThCSkpKVGZMYXZOMkdpdVl6a01oRFRlVl9scThaN1E?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex (CLDX) director receives grant of 26,000 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOQVVpbG40SnBYY0l4bTRRN1pkN2t6Sy1rY2Z5cHM4cDk5eTJvTndWZ3lqSWJQbmQwc2EyZHNYbkFxcXRPclM1SUEwVzBEaVFNOU4wUjBRbWo5dEcxd1NJb3FVSTd5dTFwWkxLNHlPcGczWEZmdGVEcVMxMi1NTEZqM3hpNUxfNEV4cFJrcjdGTllXODZERi1iSDR0WGhFWlljTDc5eG9HdjktZmQtVGc1c1Q0Y3JaYVd4VVE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex (CLDX) director James Marino awarded options on 26,000 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPMS1fU1JUc1NmTHVjV3YzRVQyM2dwYVNDWjFWVUJ6ZTZ3dTJnaVVQSUtDRUNQYko0T0gyTXpFMnM5dU1GY0prdUpBMzlhUTdaTVBrQUdaeEdCTHQ0akVjbC1rSW82RGRzRUxXVm15QWdZT2dSMllsT2pTY1BNN1lRN2NLTk5hcWVNWUhFUkZmSi1VdlE5cWVRYW01ZXQyMWVqNHBQdGoyTFM3bE9ER21CSVppR19tNVFIclE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex (CLDX) CEO Anthony Marucci receives grant of 375,000 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQSHJIaDlrRjJHVTVqZW1HRnQ0cjZwQ3A5QldnbUtMZXAzdmxZNlRtVkRVTkJRbzJBMWN6UTBSMDE2cHltT2hlZkY5d3lxcjJHdFNIQ3dZSlNxazVGbWFXdWNNR2UyZVAyMTFpR0dsNEZ3TWs2UGxiTW9kYjMyc2JEWklHZEw2T0JHSFF0c2Q2NGZnSHVxUW1PcDdfRmZhZ0dPX0JPOEF3TjVwSFJUNGV2Qm9KMEhRWF9JY3c?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex (NASDAQ: CLDX) grants 100,000 options to senior VP & CPDO", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNc1FBV1JaRDN2alJqRnBnWnhucllxSWFBdjkzTGUwQWdjaVpNdmhhTTVILWpWbV9YakREVUxvMWhDR2FfMjZkQTZyY3VISGttbXpzUVFkTTd6a1hoMjlvTVJnWTFhc3F6WmJwZ0VwbmFRN1hadmNOZi1lWHVZQzZvcEdDRTVMNVlTY2RPY0h4enh5Qm5iVlZHTlIyVHNpczMta2RuTUxtSFJ2VGpfN3M5S0J6S1Q4djBDNVE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Therapeutics, Inc.(NasdaqCM: CLDX) added to Russell 3000E Growth Benchmark", "summary": "Celldex Therapeutics, Inc. (NasdaqCM: CLDX) has been added to the Russell 3000E Growth Benchmark, as announced on June 28, 2026. This news follows several other recent updates for the clinical-stage biotechnology company, including presentations of long-term barzolvolimab results", "url": "https://www.marketscreener.com/news/celldex-therapeutics-inc-nasdaqcm-cldx-added-to-russell-3000e-growth-benchmark-ce7f5fdeda89f324", "source_name": "marketscreener.com", "published_at": "2026-06-29T03:40:35", "published_display": "29 Jun 2026 03:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Celldex Therapeutics, Inc. \u2013 NASDAQ:CLDX", "summary": "This article provides an overview of Celldex Therapeutics, Inc. (NASDAQ: CLDX) focusing on its enterprise value to EBIT forward. The content appears to be a financial data page from TradingView, offering financial metrics and other related company information.", "url": "https://www.tradingview.com/symbols/NASDAQ-CLDX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T16:39:13", "published_display": "28 Jun 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Celldex Therapeutics, Inc. \u2013 SWB:TCE2", "summary": "This article displays the \"Price to earnings forward\" metric for Celldex Therapeutics, Inc. (SWB:TCE2) on the TradingView platform. The page shows that the market is closed, with no trades, and provides navigations related to financial data, news, community, forecasts, and other ", "url": "https://www.tradingview.com/symbols/SWB-TCE2/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T03:10:38", "published_display": "28 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Therapeutics, Inc.(NasdaqCM: CLDX) added to Russell 2000 Growth Benchmark", "summary": "Celldex Therapeutics, Inc. (NasdaqCM: CLDX) has been added to the Russell 2000 Growth Benchmark. This news highlights the company's inclusion in a significant small-cap growth index, signaling increased visibility and potential interest from growth-focused investors. The clinical", "url": "https://www.marketscreener.com/news/celldex-therapeutics-inc-nasdaqcm-cldx-added-to-russell-2000-growth-benchmark-ce7f5fdede8ff727", "source_name": "marketscreener.com", "published_at": "2026-06-27T14:09:01", "published_display": "27 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex (CLDX) shareholders back larger equity plan and all directors", "summary": "Celldex Therapeutics, Inc. shareholders at their 2026 annual meeting approved an amendment to the 2021 Omnibus Equity Incentive Plan, increasing shares available for issuance by 3,400,000 to a total of 12,900,000 and clarifying tax withholding terms. All director nominees were el", "url": "https://www.stocktitan.net/sec-filings/CLDX/8-k-celldex-therapeutics-inc-reports-material-event-3de264792fdd.html", "source_name": "Stock Titan", "published_at": "2026-06-26T13:10:40", "published_display": "26 Jun 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/celldex-presents-long-term-barzolvolimab-142100448.html", "source_name": "GlobeNewswire", "published_at": "2026-06-14T14:21:00+00:00", "published_display": "14 Jun 2026 14:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/celldex-presents-positive-first-human-091500876.html", "source_name": "GlobeNewswire", "published_at": "2026-06-14T09:15:00+00:00", "published_display": "14 Jun 2026 09:15", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Therapeutics (CLDX) Stock Valuation Check After Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPX1VNNHg3NFdBQVFVc2IyUThYMGY1X2ZDQlJsWGZKbUpMdWEwc241UWNuVmpwaFp4SDByY2RVTGVHVGNqSEJTaFgxSFphZmsyT1c0NDBWVHhGZlZBWG90SVFKY0tFaUZENlZmTjlFakhGZ3FEbHZkNUlQRUd4VjgyandJdEhKX0pyaHZsTDhUUVdqOTFuLVgwbHNXSWFGOGI5aENrYVZ0bGRqUQ?oc=5", "source_name": "Market source", "published_at": "2026-06-14T07:00:00+00:00", "published_display": "14 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Data At 2026 EAACI Puts Mast Cell Pipeline In Focus", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/celldex-announces-multiple-upcoming-presentations-200100578.html", "source_name": "GlobeNewswire", "published_at": "2026-06-10T20:01:00+00:00", "published_display": "10 Jun 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UBS Adjusts Price Target on Celldex Therapeutics to $45 From $38, Maintains Buy Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/ubs-adjusts-price-target-celldex-135904970.html", "source_name": "MT Newswires", "published_at": "2026-06-10T13:59:04+00:00", "published_display": "10 Jun 2026 13:59", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "State Street (CLDX) reports 2.8M shares, 4.2% stake in CELLDex Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPaWpJaE9iLS1sQUJocW0zZk9nZVlNZFVyNkxESHVjeVBGZG81TTVLd3huRk8tOE9LMS1uYXFoeTlpLVJxUnNuMmhHcXZLN0VuR25RcmlHcWp6QUo2YmdpQS1CUUR4LVdxVU1ZTk5PbzlBcnJLRzdEVU5sbW5pTjVDMlZkSkZTWmJ0VEhrMk9HWnktMHJ0c3VkRHZENnZySUNSeUpvc2NlQ1FlYW1Nelh1cHREUzhlU1Jhei1IMGJXcWdqRkZuT3BYV1pPTQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex: A Mast Cell Reset Story Hiding Inside A CSU Trial (NASDAQ:CLDX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPS2JJWGpFSGhQSnYzenpqZUhPRWlDTVZIZHowWmxNNkdjWEI5b011WnZJTUx2aEFGSmZCWVA3ZTZNMGFiQVhFSlBQakxjM2VrMnJtWFM1VVdlWENGakxLMkpMUEZpUHQzMS11eUY5YlFoTlgxSi1iNTJnUkFPS1UzSVZ6ZXNCVnBibHFRTy1qLUhQYUVvMGRRQ0JGYWdUbVEtZ09FeA?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQcVlGWTVEZjFwMTMydm1mWVVkTGxBOVlTX1RYdWZDaW9zcUE2TEJaaFF3QWhkMk5UU0w3RHAwLUdiRDdRbHBjdnJZYkpnQlhBRWktZDhaTFo4NG9jeHhRcjU4TGl0U2hCWVg3NnltWTlrVW5ZMjlkSF9fMUh2cEJEYWJmeEs4eVU5UEJUOXBLN1ZOaURHeEF2V0RZYTBRZnFfSmVDM2ltRmo?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex sells nearly 11.9M shares, raises $345M in stock deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNVU1lV05SUG1qQl9zQTlodV8yNGV1MUxWWUpBMm5TU3JqOGcwc1B2YkM4X3d5UGZ1QjJMVm9PMWpZS0lVRkhKb3JEeklDOExVNlNBMzRoVmR1cFZ6YXdqcHdYUTBxY09fWklLWmQ2eUNqUzNDaTYwa196QU5GSUVPREF5VUpicFZ4REx1ZzludmZ6RDFzUGtaeTQzYy1SczRaQ1gtTlhXOUlPRVhWVjk0Tk40cW8yTERoZGc3N2tQZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Therapeutics Completes $345 Million Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOWGJFT09Kbm5qallUX3UxaTJnS3ZGRm5oY2NFd01wbkZ4VlRxN2M1ZmhLa2IyUVRkd1BlR2FWelo3S2R6TlZ5aW9ydEFJNVJ0NDA5clRvQW53UTRRM0VtLXVwbWd2dHRXU25CNHpucTRFX0F5d3pxZVUxQ1RhTUp0a0V0Y2JKX3dfVmFHaUI4RHVROTg5MU53dk5ET3pRQ1hxMUJoblZUbUh5UGluYTlV?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex (NASDAQ: CLDX) raises $300M in new common stock sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPYnV4N3ZKdjc1OVl2Vno3ckp5NFBfT1NoeHhUYWNaUEs3bDFpQ1JFSmw3al9FTlRuVV9URFI3RlpmVjE2b0ZIVEQ4V05LZHo2Q29MeUVYN19wY1ZTcnY0WjA5UGJ3MGVlR3QyLUNPZk9Ra1U2Y2MzMG92S1dXUnZzUkFIZlRFa2R1V1hEdEotV0t5MjdCdDY0WGNydERIZzBSbjdRd1VNRGtOcWhvbWk0SHFKbw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Celldex\u2019s US$300 Million Follow-On To Fund Barzolvolimab Altering The Investment Case For CLDX?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOelFjSlZ6b3IxTmNIWVFoa0Y4ZVRHaEQ3d1FKNGc4bndUSS04VU9ZS3pUR1JHNUoyMV91emRkY0Q1dXhnd1ZkNFVxZjNLUHZkV01qUDU0QW9OWFZPZUt1MTd4TGp6czhtdWtkS1RWOHEtNFQ3VldoaGE0M1N2SlFWUlFuVXNOT21RX3VFMXk0eEo4YWVFaEM4?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Announces Proposed Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQRThLNTdFbkk2T2F1ME9EZmRLSkUtNjlmbXRpWk54WmYzbGotNmsxZzhIV2VPWVp1LVBBVHZVWnlMcE9TU2Zvcm9Wcm1rdThiUVpWSllORF85MHZGNFZ5blpaM3dWVXQzWS05SnhLWlhYb3RIb1lzTy12MmdmY0FrbDhwSjdPYzdrQzFnT0k2eUFaZ19wMnByX2ZhSW9SQnlFQ1lqUnNxTHZ0clk5NTI3cFhJUjhVQVBQTEVPU19YVnVTZ1k3TXJBMlJpRjc?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celldex Therapeutics (CLDX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE00bjlEU1p6YV9qVS1VdGtaOTlYWnhfYm56M08wT3dVdEFNWlRWUS1CQWxsZkZjNTVIUDFXbWRhY2tsS2VzZ2MzdkgyZlBtSmZleUpBamUyTGZLUQ?oc=5", "source_name": "MarketBeat", "published_at": "2015-06-05T09:00:18+00:00", "published_display": "05 Jun 2015 09:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avant Stock Spikes after Merger Agreement with Celldex", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOOFB2Q21oRkRuTGZNb0RKcVI4R0p0d0hTT0VlSDlFSExPTnVFbjhxWHVFN3Q4UXRrWmxiNWhyMlJiWFJIZjduOHNEdkFCT2txV1F6b3V3b2tYUjhFYVJyMlhVU3NTaHZLWnpXcEN5QWRoQm1BUWRrQkY3Vm1qRUxwZUFSY3E3SS1WWHFkNDhyelI?oc=5", "source_name": "Genetic Engineering and Biotechnology News", "published_at": "2007-10-22T07:00:00+00:00", "published_display": "22 Oct 2007 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 96, "total_relevant": 59, "sentiment_summary": {"positive": 15, "negative": 3, "neutral": 41, "score": 54, "total": 59, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 21.25, "count": 38}, {"event": "earnings", "label": "Earnings", "weight": 6.6, "count": 14}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 15, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 39.11, "latest_week": "2026-07-10", "one_week_move": 1.9, "four_week_move": 25.1, "twelve_week_move": 13.2, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.508039, "market_dynamics_buy_signal": false, "relative_strength": 21.227918, "fair_value_gap": 31.8, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 48.7647, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+1.9% over one week, +25.1% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 64, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 22}, {"label": "Market source", "count": 9}, {"label": "TradingView", "count": 6}, {"label": "GlobeNewswire", "count": 5}, {"label": "simplywall.st", "count": 4}, {"label": "MT Newswires", "count": 2}, {"label": "Sahm", "count": 2}, {"label": "marketscreener.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 51}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 38}, {"label": "Earnings", "count": 14}, {"label": "Deals and strategy", "count": 3}, {"label": "Regulatory and legal", "count": 2}, {"label": "Balance sheet", "count": 1}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "51", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+1.9% over one week, +25.1% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Celldex Therapeutics CFO Plans to Retire in 2027"}], "updated_at": "2026-07-16T11:42:49.620937+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}